Oops! This Content is Members Only
The content you’re trying to view is for members only. Please register in order to access this content.
Registered users, please login to access this content.
- FDA Approves Selinexor for Heavily Treated RRMM Patients
- Video Highlights from ASCO and EHA 2019
- World Myeloma Forum being rebranded as Myeloma360
- Phase 3 OPTIMISMM Trial Demonstrates Improved Progression-Free Survival
- Poseida Therapeutics Receives FDA Orphan Drug Designation For P-BCMA-101 For The Treatment Of Multiple Myeloma
- Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
- Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
- What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
- Medicare to raise reimbursement for CAR-T cell therapies
- Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
Carfilzomib Does Not Improve Outcomes In Newly Diagnosed Myeloma Compared To Bortezomib
Competition Heats Up in BCMA CAR-T as J&J, BMS Update Myeloma Trials
Carfilzomib Is Not Superior To Bortezomib In Delaying Multiple Myeloma Progression After Initial Treatment
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
DREAMM-2 And DREAMM-6 Data At ASCO Reinforce The Potential Of GSK’s Investigational Belantamab Mafodotin In Patients With Relapsed/Refractory Multiple Myeloma
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program